Home Lifestyle New long-acting injection beats Truvada pill in HIV prevention trial

New long-acting injection beats Truvada pill in HIV prevention trial

123
Truvada pill
SAN ANSELMO, CA - NOVEMBER 23: Bottles of antiretroviral drug Truvada are displayed at Jack's Pharmacy on November 23, 2010 in San Anselmo, California. A study published by the New England Journal of Medicine showed that men who took the daily antiretroviral pill Truvada significantly reduced their risk of contracting HIV. (Photo Illustration by Justin Sullivan/Getty Images)

New long-acting injection beats Truvada pill in HIV prevention trial. The drug trial involving men who have sex with men was stopped early by an independent monitoring board after cabotegravir was found to be 69 per cent more effective than the current standard of care, Truvada, the British drugmaker said on Monday.

GlaxoSmithKline said an injection every other month of its cabotegravir drug was shown to avert an HIV infection more effectively than Gilead’s daily Truvada pill, potentially giving its ViiV unit a foothold in HIV prevention.

But the market segment GSK is eyeing is about to become more competitive as cheaper generic versions of Truvada are expected to be launched in the United States in September, as the patent expires.

Gilead, for its part, hopes that Truvada users will opt against the cheaper copies and switch to its new daily pill Descovy, approved in October 2019 after it was shown to be less toxic to the kidneys and bones.

Truvada generated US$2.8 billion in sales last year, both from treatment and preventing an HIV infection. Kimberly Smith, ViiV’s head of research, said a long-acting injection was a better route of administering because users have shown to struggle with a strict routine of daily pills, heightening the infection risk.

“Individuals have to show up every eight weeks in the clinic for the injection but in-between there is not a need to take a pill daily, so you really change the equation for adherence with a long-acting (drug),” Smith said.

GSK, which is trailing Gilead in the HIV treatment market, will speak to drug regulators about a possible approval of cabotegravir based on the prevention trial, a spokesman said.

Prevention “has turned into a multi-billion opportunity for Gilead but we think consensus estimates include little or nothing for GSK in this market,” UBS analysts said in a research note.

GSK has won approval in Canada for cabotegravir as one of two key ingredients in long-acting HIV treatment combination Cabenuva, whereas in the United States, the company has run into delays seeking the go-ahead for Cabenuva.

An initial readout from the trial, which started in late 2016, was previously not expected before next year. A similar trial to test the cabotegravir injection to prevent HIV in women is still ongoing.  Pfizer and Shionogi & Co Ltd hold small stakes in GSK’s HIV-focused ViiV Healthcare division.

Source – Zimlive

In other news – Olinda leaks chats with Stunner after the rapper did a live video claiming he doesn’t talk to Olinda anymore: Pics

Olinda leaks chats with Stunner after the rapper did a live video claiming he doesn’t talk to Olinda anymore: Pics. And the drama never ends for Olinda chapel. Whenever she posts something she makes sure its always eye-catching and attracts the media.

stunner-and-Olinda

Her latest posts have caused havoc and commotion on social media after publishing pictures that reveal she has been…continue reading.

If you suspect you have COVID-19 infection or wish to obtain more information on this disease, please call the Ministry of Health and Child Care on toll-free hotline number 2019 for assistance +263714734593 or +263774112531